Nasdaq
$38.50▲ 1.13%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.05BShares out 53.2M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
16- 10.2After-hours26.10.03 06:35SCHEDULE 13GOwnership#●●●
Axogen, Inc.
Divisadero Street Capital Management, LP and its affiliates filed a Schedule 13G on October 2, 2026, regarding their ownership of Axogen, Inc. common stock. The filing includes a joint filing agreement to formalize the reporting of equity holdings managed by William Zolezzi.…more
$38.50+1.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.1After-hours26.10.02 06:258-KKey event
Axogen, Inc.
Axogen completed the acquisition of BioCircuit Technologies on October 1, 2026, securing the FDA-cleared sutureless nerve repair device, NerveTape. The company expects NerveTape to contribute approximately $6 million in revenue for Q4 2026 and $34 million in 2027. Axogen maintains its full-year 2026 guidance of at least 24% revenue growth, a gross margin of at least 73%, and positive free cash flow.…more
$38.50+1.13%vs prev closeView filingShare - 9.10After-hours26.09.11 05:56424B5Offering
Axogen, Inc.
Axogen has announced a common stock offering of 4,910,000 shares at a price of $42.50 per share, aiming to raise $208.675 million. The proceeds are primarily intended to fund the acquisition of BioCircuit Technologies and for general corporate purposes. The underwriters have been granted a 30-day option to purchase an additional 736,500 shares.…more
$38.50+1.13%vs prev closeView filingShare
15 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.14Pre-market26.10.14 20:00#●●●#●●●
Axogen to Report Third Quarter 2026 Financial Results on October 28
Axogen announced that it will release its financial results for the third quarter of 2026 on October 28, 2026. The company will host a conference call and webcast following the release to discuss its performance.…more
$38.50+1.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.1After-hours26.10.02 06:19
●●●●●●●● ●●●●● ●●●●●●
Axogen has finalized its acquisition of BioCircuit Technologies, the developer of the FDA-cleared nerve repair device NerveTape. The company expects the acquisition to contribute approximately $34 million in revenue by 2027, expanding its surgical product portfolio.…more
$38.50+1.13%vs prev close - 9.10Regular26.09.11 01:31
●●●●●●●● ●●●●● ●●●●●●
Axogen has agreed to acquire medical device firm BioCircuit for $200 million to expand its nerve repair portfolio. To fund the acquisition, the company launched a public offering of common stock, leading to concerns over share dilution.…more
$38.50+1.13%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report